Estimated glomerular filtration rate but not solute carrier polymorphisms influences anemia in HIV–hepatitis C virus coinfected patients treated with boceprevir or telaprevir-based therapy

Abstract

eGFR, but not SLC polymorphisms, influences anemia in HIV-hepatitis C virus coinfected patients receiving boceprevir-based or telaprevir-based therapy. RBV is still a cornerstone of hepatitis C treatment, thus renal function and RBV Ctrough should be monitored in patients receiving RBV regimen combined with first-generation direct-acting antiviral agent.